NCT00595257已完成1 期
Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Non Reconstructable Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- avoid amputation
研究概览
简要总结
The purpose of this study is to determine if concentrated nucleated cells from your own bone marrow, injected or infused into an ischemic limb, will restore sufficient blood flow to avoid amputation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Critical Limb Ischemia per protocol (see diagnostic criteria #2) with regard to the study limb.
- •Existence of a PAOD with clinical presentation corresponding to Rutherford Category 4 or Category 5 as defined in the reporting standards adopted by the Society of Vascular Surgeons (table 1)
- •Patient meets at least one of the following diagnostic criteria in the study limb:
- •Ankle artery occlusion pressure absolute <50 mmHg or ABI <0.4
- •Toe artery occlusive pressure < 40mm Hg or TBI (<0.4)
- •TcPO2 <20 mmHg lying down breathing room air, if available.
- •There is no reasonable open surgical or endovascular revascularization option as determined by the treating vascular specialist. Factors that may contribute to the determination of inoperability may include:
- •Anatomical considerations
- •No outflow targets
- •No appropriate conduit (i.e. vein for bypass)
- •Long segment occlusions or calcified lesions that predict poor outcome with endovascular approaches.
- •High risk medical conditions
- •Unstable cardiac disease.
- •Renal insufficiency
- •History of prior failed revascularization attempts
- •The patient's unsuitability must be confirmed by 2 qualified physicians.
- •The attending vascular surgeon will provide the primary assessment.
- •The confirmatory opinion must come from a fully licensed physician. (not a resident)
- •If anatomical considerations are invoked, the second physician may be a vascular surgeon, interventional radiologist, cardiologist, or vascular medicine specialist.
- •If medical co-morbidity is deemed the high risk aspect, then the confirmatory opinion may be obtained from an internist, family physician, cardiologist, vascular medicine, nephrologists, or vascular surgeon.
- •Age >18 years and ability to understand the planned treatment
- •Subject has read and signed the IRB/IEC approved Informed Consent form
- •Patients for whom the following medication(s) is prescribed must have a one month stable baseline of appropriate/maximally tolerated therapy prior to enrollment: Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or blood pressure medication
- •Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery.
排除标准
- •Life expectancy <6 months due to concomitant illnesses
- •History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation
- •Terminal renal failure with existing dependence on dialysis
- •Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free..
- •Poorly controlled diabetes mellitus (HgbA1C>10%)
- •Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5
- •Life-threatening complications of the ischemia necessitating immediate amputation
- •Uncorrected iliac artery occlusion on index side
- •Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6)
- •Active clinical infection being treated by antibiotics within one week of enrollment
- •Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day).
- •Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method.
- •Underwent a major cardiovascular surgical procedure (carotid endarterectomy, open arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or an adverse cardiovascular event (stroke or MI) within the 30 days prior to randomization
结局指标
主要结局
avoid amputation
时间窗: 60 days
次要结局
- measurement of hemodynamic response(60 Days)
研究者
研究点 (2)
Loading locations...
相似试验
终止
不适用
Autologous Mesenchymal Stem Cell Transplant for Parkinson's DiseaseParkinson's DiseaseNCT00976430Jaslok Hospital and Research Centre5
已完成
2 期
Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF FailuresInfertility, FemaleInfertility of Uterine OriginAsherman SyndromeNCT03166189D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology46
已完成
2 期
Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the HipAvascular Necrosis of the Femoral HeadNCT02065167Universidad Autonoma de Madrid26
已完成
1 期
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb IschemiaCritical Limb IschemiaNCT01472289TotipotentSC Scientific Product Pvt. Ltd.17
已完成
1 期
Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke PatientsIschemic StrokeNCT00859014The University of Texas Health Science Center, Houston25